Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 1/20 | 0.54 |
| ▸ | ANPEP | P15144 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
| ▸ | PEPD | P12955 | 2/20 | 0.38 |
| ▸ | XPNPEP1 | Q9NQW7 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8005260 | 1.00 | MMP2 (0.54) | MMP2ANPEPTP53CASP3POLB | |
| SCHEMBL27509233 | 1.00 | MMP2 (0.54) | MMP2ANPEPTP53CASP3POLB | |
| SCHEMBL16382428 | 0.95 | MMP2 (0.53) | MMP2ANPEPTP53CASP3POLB | |
| SCHEMBL692909 | 0.85 | CASP3 (0.46) | MMP2ANPEPTP53CASP3POLB | |
| SCHEMBL30149224 | 0.85 | CASP3 (0.46) | MMP2ANPEPTP53CASP3POLB | |
| SCHEMBL1523018 | 0.85 | CASP3 (0.46) | MMP2ANPEPTP53CASP3POLB | |
| SCHEMBL7338741 | 0.84 | CASP3 (0.45) | MMP2ANPEPTP53CASP3POLB | |
| SCHEMBL9131956 | 0.84 | CASP3 (0.45) | MMP2ANPEPTP53CASP3POLB | |
| SCHEMBL28847883 | 0.84 | CASP3 (0.45) | MMP2ANPEPTP53CASP3POLB | |
| SCHEMBL23897220 | 0.81 | CASP3 (0.49) | MMP2ANPEPTP53CASP3SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4743175-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | Aconcagua Bio, Inc. (US) | 2026-05-20 | — | — | EP | disclosed |
| US-20250051355-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | ACONCAGUA BIO, INC. | 2025-02-13 | — | — | US | disclosed |
| WO-2025015269-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | ACONCAGUA BIO, INC. (US) | 2025-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250051355-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | IAPP, GIPR, GPR119 | MMP2 2301/4885ANPEP 563/4885TP53 2343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.